FMC63, an IgG2a mouse monoclonal antibody, targets CD19. To date, a majority of the reported CART19 trials include the anti-CD19 scFv extracted from FMC63, such as both the FDA-approved CARs ...
An alternative to antigen-specific expansion is the transduction of patient T cells, usually via lentivirus, with a chimeric antigen receptor (CAR) specific for a tumor antigen. Such receptors are ...
News Medical on MSN5d
Engineered SNIPRs transform CAR T-cell precision for safer cancer therapyResearchers developed SNIPRs, innovative receptors that sense soluble ligands, enabling precise therapeutic control in CAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback